Viracor-IBT partners with The National Kidney Registry to accelerate living donor transplantation

Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, is pleased to announce a partnership between The National Kidney Registry (NKR) and Viracor-IBT Laboratories, a wholly-owned subsidiary of Eurofins, to streamline pre-transplant serology testing for kidney donors. The NKR selected Viracor-IBT as the national laboratory to perform infectious disease screening for its 75 member centers. Fast and accurate preoperative serology testing reduces paired kidney exchange or "swap" failures and increases the number of patients transplanted in NKR facilitated swaps. With so many lives involved, time is of the essence and streamlined logistics are critical; delayed test results can delay transplants.

In describing the selection of Viracor-IBT for national laboratory services, Garet Hil, Founder and CEO of the NKR said, "Infectious disease screening is a critical part of the paired exchange process. These tests need to be fast and accurate; otherwise swaps can be delayed, or worse, cancelled. Through our partnership with Viracor-IBT we further streamline the pre-op serology testing process, reducing the turnaround for these tests to under two days from as much as 10 days, while providing secure electronic transmission of the results."

Julie Kliegl, President of Viracor-IBT added, "Like the NKR, Viracor-IBT is passionate about helping transplant patients. As a laboratory committed to providing test results faster when it matters most, Viracor-IBT is thrilled to partner with the NKR on this critical program that accelerates donor-recipient matching and increases living donor transplantation."

The NKR and Viracor-IBT are continually working together to identify additional areas in which this collaboration can benefit transplant donors, recipients and hospital services.

For more information please contact: